BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that it
is expanding the clinical development program for its lead drug candidate
MBP8298. The drug is currently undergoing an international pivotal phase
II/III clinical trial with secondary progressive MS patients (SPMS). BioMS now
plans to initiate a clinical trial for MBP8298 in relapsing-remitting MS
(RRMS) patients in the second half of 2006.
